drugset / Trial / NCT00461305

Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea

NCT00461305

Phase 2/3 Completed 420 enrolled Bayer
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to investigate efficacy of ethinylestradiol for intracyclic bleeding profile in patients with dysmenorrhea and to investigate the long term safety

Timeline

Start
2007-02
Primary completion
2009-01
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 20 ug Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications